
The product portfolio of Merck Serono includes leading prescription drugs such as the cancer drug Erbitux® and the multiple sclerosis treatment Rebif®. In addition, the division offers therapies to treat infertility, growth disorders, as well as cardiovascular and metabolic diseases. Research and development activities are focused on Oncology, Neurodegenerative Diseases, as well as Autoimmune and Inflammatory Diseases.
Merck Serono specializes in innovative pharmaceuticals. In order to succeed, Merck Serono is resolutely pursuing activities in selected indications for highly specialized therapeutic areas mainly treated by specialists. In 2009, Merck Serono generated around 60% of its sales with its five top-selling biopharmaceuticals. Merck Serono is a medical biotechnology leader in Europe. In order to further reinforce this position, we are currently expanding our state-of-the-art biotechnology manufacturing facility, located in Switzerland.